Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)
|幽門螺桿菌檢驗:體外診斷市場分析及預測模式 Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)|
|出版日期: 2020年08月30日||內容資訊: 英文||
Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Helicobacter Pylori Tests market for the year 2020 and beyond. H. pylori has been recognized as a Class I carcinogen by the International Agency for Research on Cancer and as one of the strongest known risk factors for gastric malignancies like peptic ulcer disease, gastric MALT lymphoma and gastric cancer as 89% of all gastric cancers are related to H. pylori infection.
The occurrence of infection is mainly observed during childhood in large number of population. It gets transmitted from mother-to-child in developed countries, but horizontal transmission is not observed in developed countries due to better sanitary conditions.
The prevalence is lower in developed nations with a prevalence rate of 15.5% when compared to the developing countries having a prevalence rate of 93.6%. The main causes for the high prevalence of infection are poverty enhanced level of transmission due to malnutrition, poor hygiene and unaffordable heath care indicating low socioeconomic status in regions like Asia, South America and Africa. Helicobacter Pylori Tests is segmented into Helicobacter pylori Breath Test, Helicobacter pylori Feces Test, Helicobacter pylori IHC Test, Helicobacter pylori Serology EIA Test, Helicobacter Pylori Point of Care (POC) Tests and Helicobacter Pylori Other Tests.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Helicobacter Pylori Tests and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered - Otsuka Holdings Co Ltd, Avanos Medical Inc, Abbott Laboratories, Meridian Bioscience Inc, DiaSorin SpA, Thermo Fisher Scientific Inc., and Others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
Who should buy this report?
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -